文献速递间质性肺疾病

抗纤维化药物对特发性肺纤维化的临床有效性

Clinical Effectiveness of Antifibrotic Medications for Idiopathic Pulmonary Fibrosis.
PubMed 文献 · Am J Respir Crit Care Med · 2019-01-01

基于美国大型保险数据库纳入8098例特发性肺纤维化患者,经倾向评分1:1匹配比较抗纤维化药物治疗组(n=1255)与未治疗组(n=1255)。抗纤维化药物与全因死亡风险降低相关(HR 0.77,95%CI 0.62-0.98,P=0.034),但仅见于治疗前2年;急性住院也减少(HR 0.70,95%CI 0.61-0.80,P<0.001)。吡非尼酮与尼达尼布之间全因死亡无显著差异(HR 1.14,95%CI 0.79-1.65,P=0.471)。

要点

  • 抗纤维化药物与全因死亡风险降低相关,但仅见于治疗前2年。
  • 抗纤维化药物与急性住院风险降低相关。
  • 吡非尼酮与尼达尼布之间全因死亡无显著差异。

核心结论

  • 在特发性肺纤维化患者中,抗纤维化药物可能与非治疗相比降低全因死亡和住院风险。

研究设计与样本

  • 创建1:1倾向评分匹配队列,比较抗纤维化药物治疗组(n=1255)与未治疗组(n=1255)。

主要发现

  • 抗纤维化药物与全因死亡风险降低相关(HR 0.77;95%CI 0.62-0.98;P=0.034),但该关联仅存在于治疗前2年。
  • 治疗队列急性住院减少(HR 0.70;95%CI 0.61-0.80;P<0.001)。
  • 吡非尼酮与尼达尼布之间全因死亡无显著差异(HR 1.14;95%CI 0.79-1.65;P=0.471)。

临床怎么用

  • 对特发性肺纤维化患者可考虑使用抗纤维化药物以降低早期死亡和住院风险。
  • 选择吡非尼酮或尼达尼布时,全因死亡风险未见显著差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: Since their approval, there has been no real-world or randomized trial evidence evaluating the effect of the antifibrotic medications pirfenidone and nintedanib on clinically important outcomes such as mortality and hospitalizations. Objectives: To evaluate the clinical effectiveness of the antifibrotic medications pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis. Methods: Using a large U.S. insurance database, we identified 8,098 patients with idiopathic pulmonary fibrosis between October 1, 2014 and March 1, 2018. A one-to-one propensity score-matched cohort was created to compare patients treated with antifibrotic medications (n = 1,255) with those not on treatment (n = 1,255). The primary outcome was all-cause mortality. The secondary outcome was acute hospitalizations. Subgroup analyses were performed to evaluate mortality differences by drug. Measurements and Main Results: The use of antifibrotic medications was associated with a decreased risk of all-cause mortality (hazard ratio [HR], 0.77; 95% confidence interval [CI], 0.62-0.98; P value = 0.034). However, this association was present only through the first 2 years of treatment. There was also a decrease in acute hospitalizations in the treated cohort (HR, 0.70; 95% CI, 0.61-0.80; P value <0.001). There was no significant difference in all-cause mortality between patients receiving pirfenidone and those on nintedanib (HR, 1.14; 95% CI, 0.79-1.65; P = 0.471). Conclusions: Among patients with idiopathic pulmonary fibrosis, antifibrotic agents may be associated with a lower risk of all-cause mortality and hospitalization compared with no treatment. Future research should test the hypothesis that these treatments reduce early, but not long-term, mortality as demonstrated in our study.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Dempsey TM, Sangaralingham LR, Yao X, et al. Clinical Effectiveness of Antifibrotic Medications for Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2019. PMID: 31150266. doi:10.1164/rccm.201902-0456OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。